New at Switzerland Innovation Park Basel Area: SunRegen
The biopharmaceutical company SunRegen Healthcare develops a therapy for neurodegenerative eye diseases like Optic Atrophy. The two co-founders and managers Dr. Yuhong Dong and Mr. David Guan moved their young startup to the Switzerland Innovation Park Basel Area in Allschwil in January 2019.
Yuhong Dong and David Guan, SunRegen Healthcare
In 2020 they hope to reach the next milestone and move their project from preclinical to clinical stage for their lead compound SBC003. This synthetic molecule is derived from a natural active ingredient that can be found in a medical herb used in the oriental medicine. Yuhong and David plan to test their compound for ALS as another target indication. Further, they want to test SBC003 for other neurological and neuromuscular diseases such as Alzheimer’s, Parkinson’s or Huntington’s disease.
At the Switzerland Innovation Park Basel Area in Allschwil, the co-founders concentrate on developing their business. They are especially happy that they were able to move in and start working right from the beginning, thanks to the furnished office. To host visitors, they appreciate the coffee area that is open to all residents as well as the meeting rooms the Switzerland Innovation Park Basel Area offers. “Even before we could afford an office, the team at the Switzerland Innovation Park was very forthcoming. They are always very friendly – we really enjoy being here.”
SunRegen Healthcare is one of the participants of the first round of the BaseLaunch accelerator. Back in 2017, Yuhong and David reached Phase I of the program, benefitting from customized coaching and funding for three months. Although they were not selected for phase II, they persisted in building their startup. In 2018, they won the BIO-Europe 2018 Startup Slam Competition, held in Copenhagen and gained access to a top-tier mentoring program with industry experts from Johnson & Johnson.
Share this article
You might also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.Read More